Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies.

Maria Maddalena CavalluzziRoberta BudriesiMaria Antonietta De SalviaLaura QuintieriMonica PiarulliGualtiero MilaniRoberta GualdaniMatteo MicucciIvan CorazzaAntonio RosatoMaurizio VialeLeonardo CaputoCarlo FranchiniGiovanni Lentini

Published in: Pharmacological reports : PR (2020)

All above results identify lubeluzole as a possible starting compound for the development of a novel class of antibacterial adjuvants endowed with spasmolytic activity.

Keyphrases

case control
ischemia reperfusion injury
cell therapy
anti inflammatory
emergency department
stem cells
drug induced
cerebral ischemia
adverse drug
mesenchymal stem cells
brain injury
blood brain barrier
bone marrow